Innovative Medicines Initiative

                                                      WORKSHOP on ONCOLOGY

The goal of the workshop is to identify where an IMI programme could bring the most value in moving forward the oncology innovation agenda, taking into consideration the Spanish oncology community and opening a debate around the future.

Madrid, January 12th, 2017.

Venue: CNIO - Spanish National Cancer Research Centre. C/ Melchor Fernández Almagro, 3, Madrid.

Organized by:

Organized by

 Supported by:

Supported by

                                                          *** Minutes of event ***

                                                                  PROGRAMME

09:15 - 09:45 Registration

09:45 - 10:15 Opening sesión

Marta Gómez Quintanilla. Spanish Representative of IMI. CDTI

Ion Arocena. General Director. ASEBIO

Javier Urzay. Deputy General Director. FARMAINDUSTRIA

Alfonso Beltrán. Deputy General Director of international programs and institutional relations, and director of FIPSE. ISCIII.

María Blasco. General Director. CNIO

11:00 - 11:30 Innovative Medicines Initiative

Pierre Meulien, IMI Executive Director.

11:30 - 11:45 An oncology strategy for IMI

Stefan J. Scherer, Global Head Translational Precisión Medicine, Novartis; Chair of the IMI Strategic Governing Group (SGG) Oncology.

Carmen Eibe, Director, Project Coordination Department, PharmaMar.

11:45 - 13:30 The perspectives of Spain

11:45 - 12_10 María Blasco, IMI Scientific Committee member, Director of the Spanish National Cancer Research Centre (CNIO).

12:10 - 13:00 Key Speakers:

  • Andrés Cervantes, Head of Section in Medical Oncology, Hospital Clínico Universitario de Valencia.
  • Joaquín Arribas, Scientific Director, Biomedical Research Networking Centre consortium on Oncology (CIBERONC).
  • Alfonso Valencia, Director Spanish National Bioinformatics Institute (INB).

13:00 - 13:30 Debate.

15:00 - 15:30 The perspectives of the European Commission

Jan van de Loo, Scientific Officer, Non-comunicable diseases and the challenge og healthy ageing, DG Research & Innovation, European Commission.

15:30 - 16:00 The perspectives of the Spanish Agency of Medicines and Medical Devices.

César Hernández. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)

16:00 - 16:30 Next steps and concluding remarks.

Marta Gómez Quintanilla, Spanish Representative - Health & IMI - Horizon 2020, Centro para el Desarrollo Tecnológico Industrial.